Abstract
In the article is presented the case of development of medicinal hepatitis as result of irrational use of statin treatment at patient with Ischemic heart disease and nonalcoholic Fatty Liver Disease against morbid obesity. The clinical observation reflects the necessity of usage of liver protectors in prevention of possible side effects of hypolipidemic statin treatment and emphasizes the advantage of double cholesterol inhibition.
MeSH terms
-
Adult
-
Chemical and Drug Induced Liver Injury / diagnosis
-
Chemical and Drug Induced Liver Injury / etiology*
-
Chemical and Drug Induced Liver Injury / prevention & control
-
Cholagogues and Choleretics / administration & dosage
-
Cholagogues and Choleretics / therapeutic use
-
Cholesterol / blood
-
Drug Therapy, Combination
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Liver Function Tests
-
Male
-
Myocardial Infarction / blood
-
Myocardial Infarction / complications
-
Myocardial Infarction / drug therapy
-
Obesity / blood
-
Obesity / complications
-
Obesity / drug therapy
-
Treatment Outcome
-
Ursodeoxycholic Acid / administration & dosage
-
Ursodeoxycholic Acid / therapeutic use
Substances
-
Cholagogues and Choleretics
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Ursodeoxycholic Acid
-
Cholesterol